The Bridge Between Chronic Inflammation and Cancer
oxMIF, the disease-associated conformer of Macrophage Migration Inhibitory Factor (MIF), is a central mechanistic link between chronic inflammation and cancer. Selectively generated at sites of active disease and absent from healthy tissue, oxMIF enables precise therapeutic intervention without disrupting the physiological functions of native MIF.
ImmunoOne's Focus Indications:
Inflammation
Chronic inflammatory diseases are increasingly recognized as a major global health burden, with three out of five deaths worldwide attributable to chronic inflammatory conditions. As a key regulator of innate and adaptive immune responses, oxMIF drives pro-inflammatory signaling and acts as an upstream regulator of other inflammatory cytokines, aggravating disease by recruiting and activating macrophages and neutrophils thereby sustaining chronic inflammation at its source.
ImmunoOne's antibody expertise underpins a highly selective, site-restricted targeting approach exemplified by ON104, an anti-oxMIF antibody that directs therapeutic activity where it matters most, while minimizing exposure of healthy organs.
Oncology
Cancer accounts for approximately one in six deaths globally, with projections estimating over 24 million new cases and 13 million deaths annually by 2030. Within the tumor microenvironment, oxMIF actively promotes cancer cell proliferation, migration, and invasion, drives angiogenesis, enables immune evasion, and sustains resistance to apoptosis positioning it as a critical mechanistic driver of tumor progression.
ImmunoOne's antibody expertise enables a highly selective, site-restricted targeting approach exemplified by ON203, an anti-oxMIF antibody that directs therapeutic activity specifically to tumors and metastatic lesions.
By targeting oxMIF, partners gain access to multiple development opportunities across inflammation and oncology backed by a platform designed for potent, selective activity and a favorable safety profile.
Drug Target Review Issue 3, 2023